Ruti Aga and the Six-Year Ban: A Fake Prescription From a Clinic That Never Existed

An old prescription pad

The clinic on the prescription did not exist. The person who signed it was a family member with no medical registration. The pad used to write it was an old one carried over from a previous workplace — a facility that later confirmed in writing that this person had never worked there. Three independent layers of verification, three times the same conclusion. The Athletics Integrity Unit (AIU) of World Athletics needed only that much to close the heaviest part of Ruti Aga's file.

On 10 September, the sanction took effect: six years. An Ethiopian marathoner, 32 years old, 2026 Tokyo Marathon champion, three-time runner-up at World Marathon Majors races, steps off the road at precisely the point where her sporting profile was still at its peak. A return, if any, would come at 38.

I read the news on an evening in Da Nang. What stopped me was the old prescription pad, not the number six. An athlete can err. A system can err. But a pad carried over from an old job, used to write a forged document for oneself, tells a different story — one about despair.

Who Aga was on the road

To understand why this sanction hurts, you have to understand who Aga was. In 2026 she won the Tokyo Marathon, one of the six World Marathon Majors — the most prestigious tier of long-distance road racing on the planet. Around that peak she finished second at three Majors. In women's athletics, that is the absolute elite: not a one-off regional winner, but a consistent presence at the front of the hardest courses in the world.

The source does not specify which Majors those runner-up finishes came at. That detail needs verification. The tier, however, is clear: across 2026–2026, Aga belonged to the strongest group of women marathoners alive.

The triggering event was a half marathon in China in March. She won. The source discloses no time. For technical analysis that is a large gap: without a mark you cannot position the result against the course record, her personal best, or any benchmark. Any inference about the sporting significance of that win is speculation.

But one technical detail deserves attention because it is mislabelled almost everywhere. The substance was methylprednisolone. Many reports call it a "steroid". That is pharmacologically imprecise. Methylprednisolone is a synthetic glucocorticoid — a corticosteroid, an anti-inflammatory — not an anabolic-androgenic steroid. In WADA's classification it sits in class S9, prohibited in-competition only, and is designated a Specified Substance: a category more plausibly linked to inadvertent or therapeutic use.

That distinction carries enormous analytical weight. It determines the baseline sanction and the plausibility of a therapeutic explanation.

Based on my experience following road racing for close to a decade, including a stretch writing for a running magazine, I have learned that athletics fans often read doping sanctions through a football or cycling lens, where anabolic steroids are the familiar story. Road running is different. Most violations among East African marathoners involve medication, contaminated supplements, or administrative failures in declaration. That is why Aga's case has to be read at its proper level.

The arithmetic: 2 + 4

The sanction structure reads clearly: two years for presence of a prohibited substance, plus four years for tampering, served consecutively rather than concurrently, for six years total. That matches the WADA Code principle that multiple anti-doping rule violations are served consecutively.

The revealing part is the ratio. Four years for the forgery exceeds two years for the substance itself. The cover-up was punished more heavily than the underlying offence, and that is the central governance lesson of the case.

Under the WADA Code, tampering during results management is an independent, separately sanctionable violation with a four-year baseline. The athlete converted what might have been a two-year case into a six-year ban through her own conduct.

And here is the evidentiary chain the AIU assembled. The prescription came from a clinic that did not exist. The "doctor" who signed it was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace. The facility confirmed she had never been employed there. The clinic named on the prescription confirmed the document was not theirs.

There is no gap in that chain. It is the kind of file the AIU closes within days, because verification is now routine: direct clinic confirmation, registration checks, cross-checks on employment history. Forged documentation is no longer a grey zone. It is a lit zone.

Now place the story in a different scenario. Aga said the positive came from treating a knee injury. Methylprednisolone is an anti-inflammatory, entirely plausible for joint injuries. With a valid Therapeutic Use Exemption, or with a route and timing outside the in-competition window, that scenario could have produced no violation, or a reduced sanction. The source does not state the route of administration — intra-articular injection or oral, before or during competition. That missing fact decides a great deal.

Even in the worst case, however, two years is the price of a medical error. Six years is the price of a medical error plus a second offence.

The Chinese road-racing economy

One structural layer sits behind the case and the source only grazes it: the venue.

The Chinese half marathon was not a championship. It was almost certainly an appearance-fee race — a model that has defined the East African road circuit for over a decade. Chinese organisers pay to have Ethiopian and Kenyan runners on the start list; athletes collect appearance fees plus prize money for a win. For someone like Aga, that is steady income between Majors.

That economy runs on density. Many races, many trips, many consecutive weeks of competition, and far lower scrutiny at each event than at a Major. An athlete can race a dozen times a year. The chance that a small error — a painkilling injection before race day — becomes a positive test is high, and the chance of proper advice is low.

The March result is almost certainly annulled, taking the prize money with it. With a six-year ban, Major invitations vanish, appearance fees vanish, sponsorship vanishes. An elite marathoner lives on those three streams. All three close in a single afternoon.

Ethiopia does not wobble

At national level, the case leaves almost no trace on the results board.

Ethiopia and Kenya share the top of distance running, and both have a bench so deep that one individual's departure creates no gap. Aga was one node in that system. She is irreplaceable personally; the system replaces her silently.

What suffers is something else: brand credibility. Race organisers pay for an Ethiopian name because that name carries a quality guarantee. Every published doping case erodes it slightly. East African managers and agents understand this better than anyone, which is why cases like Aga's are often handled internally and quickly before reaching the public.

For the Chinese circuit, the consequence may be more concrete: organisers are likely to tighten medical and documentation vetting for invited East African athletes as a reputational hedge. The people most affected by that move will be young athletes who lack proper paperwork.

A career ending at 32

The age curve in women's marathoning is long. Peaks commonly extend past 35. At 32, Aga was at her peak, not past it. The ban lands at the point of maximum earning and competitive value.

Six years from 10 September returns her at 38. Physiologically that is not impossible — many women marathoners race well into their late thirties. But returning to Major podium level after six years away from elite competition is a very low probability. No races to hold rhythm, no rivals to measure against, no contracts to pay a support team. Six years is a silence a 38-year-old cannot fill with willpower.

This is functionally a career-ending sanction, even though on paper it has an expiry date.

The contrarian read

The common reading is that the cover-up was worse than the crime. That is correct, and it is the defensible reading.

But there is a deeper layer. Precisely because methylprednisolone is a Specified Substance, the substance side of the case was inherently the softer half. An athlete found with an anti-inflammatory during a period in which she was treating a knee injury has a genuine defence pathway. That pathway was destroyed — and the people who destroyed it were the athlete herself and those closest to her.

What is most frightening in this file is how amateurish it is. A clinic invented. A relative with no licence playing doctor. An old prescription pad. None of it resembles a sophisticated doping operation. It is what someone without legal counsel does to try to save herself, and it pushes her deeper.

That is why I reject the reading that this is evidence of a systemic problem in Ethiopian athletics. The evidence does not support it. One individual case, clumsily handled, inside a pipeline deep enough to absorb the loss without wobbling — that is the more accurate diagnosis.

The labelling matters too. Calling methylprednisolone a "steroid" inflates perceived severity among casual readers and blurs the line between a therapeutic corticosteroid and an anabolic steroid used to build muscle. That line separates a medical error from a conspiracy to cheat.

Tactics are what people see; the soul is what we need to feel. In a doping case, the visible part is the ban. The felt part is the question of why someone at the top chose to write a forged document on an old pad instead of calling a lawyer.

The answer probably lies elsewhere: many East African road runners have no lawyer to call. They have an agent, a coach, a training group. None of them is trained to handle an AIU investigation. When the file opens, they do the only thing they can think of — they produce a piece of paper. And that paper ends a career.

Where the light does not reach, dreams are still training. But there too, athletes are signing documents whose consequences they do not understand.

What remains

Six years is a sentence, but it is also a description. It describes the gap between an anti-doping system that can verify a forged prescription in days, and a layer of athletes still improvising with the tools of twenty years ago.

For Aga, the story is effectively closed. No appeal has been announced, and the evidentiary record is too tight to reverse.

For hundreds of other athletes preparing for appearance-fee races across Asia, this case should be read as a manual. Not a manual about prohibited substances, but about paperwork. Because in a sport measured in seconds, a career is sometimes decided by an old prescription pad.

The road does not judge anyone. It only records time. And sometimes it also records what people write to escape themselves.